Announcements Trials
Browse Landscape

Phase

Phase 2 27Phase 1 8Phase 1/2 3Phase NA 1

Status

Completed 3

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3

Conditions

Melanoma 3Uveal Melanoma 1

Interventions

pembrolizumab 74Nivolumab 53Ipilimumab 42Cyclophosphamide 32Interleukin-2 24aldesleukin 23Temozolomide 17fludarabine 16Biopsy 11trametinib 10fludarabine phosphate 10dabrafenib 10spartalizumab 8Paclitaxel 8Dacarbazine 8sargramostim 7cemiplimab 7binimetinib 7Cisplatin 7Bevacizumab 7poly ICLC 6lenvatinib 6epacadostat 6Radiotherapy 6Granulocyte-Macrophage Colony-Stimulating Factor 6montanide ISA 51 5encorafenib 5atezolizumab 5Vemurafenib 5Specimen Handling 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Melanoma × incomplete Freund's adjuvant × Clear all
NCT00118274 2021-04-20

Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma

University of Virginia

Phase 1/2 Completed
170 enrolled 8 charts
Dermatologic

Melanoma

NCT00062036 2017-07-02

Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
33 enrolled
Dermatologic

Melanoma

NCT00089219 2014-11-20

Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma

University of Virginia

Phase 1/2 Completed
39 enrolled
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡